# The Use of Intraoperative Intravenous Magnesium Sulfate To Reduce Postoperative Pain

# ABSTRACT

The use of non-opioid perioperative analgesic drugs such as intravenous magnesium sulfate has been advocated to reduce postoperative pain. It was unclear if intraoperative intravenous magnesium sulfate decreases postoperative opioid consumption and pain. The purpose of this work is to describe the evidence on the effectiveness of intraoperative intravenous magnesium sulfate in improving patient analgesia postoperatively. Six randomized controlled trials evaluating the effectiveness of intraoperative intravenous magnesium sulfate administration in decreasing postoperative opioid use and pain scores were critically appraised. The results of these studies consistently found patients who received intraoperative intravenous magnesium sulfate had lower pain scores and required less opioids postoperatively. Based on this evidence, a plan to implement a change in practice is described.

## PICOT QUESTION

Do adult patients undergoing surgery (**P**) who receive intravenous magnesium sulfate intraoperatively (I) compared to patients who do not receive intravenous magnesium sulfate intraoperatively (C) have less pain and use fewer opioids (**O**) in the postoperative period (T)?



Lydia laser SRNA, Nicole Johnson SRNA, Standerline Bernadin Vincent SRNA, John McDonough, Ed.D, Dr. (habil) NScA, APRN, FRSM, CRNA, Ryan Shores, DNP, APRN, CRNA, Carol Roland DNP, SPRN, CRNA

## University of North Florida, School of Nursing Jacksonville, Florida

## EVIDENCE TABLE

<b>Title Author Year</b>	Study Type	Conclu
ntinociceptive Effects of Magnesium Sulfate for Monitored nesthesia Care during Hysteroscopy: A Randomized Controlled tudy. Gao, P., Lin, J., Wang, S., Zhang, Y., Wang, G., Xu, Q., & uo, X. (2020).	A randomized control trial	50mg/kg i Total dose (control gr receiving i postoperat
nplementation of magnesium sulphate as an adjunct to aultimodal analgesic approach for perioperative pain control in ambar laminectomy surgery: A randomized placebo-controlled inical trial. Tsaousi, G., Nikopoulou, A., Pezikoglou, I., Birba, ., & Grosomanidis, V. (2020).	A randomized placebo- controlled trial	20mg/kg Postoperat -13.31, -5 group; this reduced in (p < 0.01).
lagnesium sulfate for postoperative analgesia after surgery under binal anesthesia. Shah, P. N., & Dhengle, Y. (2016).	A randomized controlled trial	<b>250mg bo</b> The VAS solve VAS score score of 4- in the mag statistically analgesia, amounting analgesia solve ( $p = 0.009$
lagnesium sulfate improves postoperative analgesia in paroscopic gynecologic surgeries: A double-blind randomized ontrolled trial. Sousa, A. M., Rosado, G. M., De Souza Brandão eto, J., Guimarães, G. M. N., & Ashmawi, H. A. (2016).	A double blinded randomized control trial	Bolus of 2 Patients the who receive morphine; hours, resp first dose of
lagnesium and bladder discomfort after transurethral resection of adder tumor. Park, J., Hong, J. S., Kim, D. H., Yu, J., Hwang, , & Kim, Y. (2020).	A randomized control trial	Bolus of 5 The incide significant relative ris similar res postoperat [2%] vs. 14 satisfaction group (5.1 not signific
ffect of intraoperative magnesium infusion on perioperative nalgesia in open cholecystectomy. Bhatia, A., Kashyap, L., awar, D. K., & Trikha, A. (2004).	A randomized control trial	Bolus of 5 The amou magnesiur significant

Evidence from 6 RCTs of surgical patients consistently found that receiving an intraoperative intravenous magnesium sulfate bolus followed by a magnesium sulfate infusion postoperatively decreased pain scores (immediately postoperative) and decreased total amount of opioid medication administration in 24h.

#### isions

#### in 100mL

of fentanyl given to patients in group magnesium was less than the one administered to group C roup) [ 100 (75-150) vs 145 (75-175) ug, median (range); P<0.001]. In addition, patients magnesium displayed lower VNRS scores at 15 min, 30 min, 1 hour, and 4 hours tively.

tive analgesics consumption in morphine iv equivalents (mean difference –9.24 [95 % CI 5.17] mg; p = 0.001) and VAS scores at all-time points of assessment were lower in magnesium s effect peaked at 4 h (mean difference -2.15 [95 %CI -3.21,-1.09; p = 0.001]. Magnesium traoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia

#### olus followed by infusion of 500 mg

score ranges were 0–3, 4–6 and 7–10. In the immediate postoperative period, no patient had a more than 6. One patient in the magnesium group and seven in the control group had a VAS -6, which was statistically significant (p = 0.006). Whereas at the 4-hour interval, seven patients gnesium group and 17 patients in the control group, had a VAS score of 4–6, which was also y significant (p = 0.001). A total of 18 patients in the magnesium group required rescue amounting to 33.3% of the group. In the control group, 29 patients required rescue analgesia, g to 53.7% of the group. The lower number of patients in the magnesium group requiring rescue was also a statistically significant difference (p = 0.033). The control group required rescue earlier than the magnesium group. The magnesium group required rescue analgesia at  $7.89 \pm$ , whereas the control group required it earlier at  $4.59 \pm 4.01$  hours in the postoperative period

#### 20 mg/kg over 20 min followed by 2 mg/kg/hr.

hat received magnesium had significantly lower morphine consumption compared with patients ved saline solution. Patients in group M (magnesium sulfate) consumed 3.38 and 5.7 mg of , and group S (saline solution) consumed 5.7 and 12 mg of morphine after 60 minutes and 24 pectively. In group M, morphine consumption was significantly lower than in group S. Time to of morphine rescue in groups M, and S were 10, 5, and 5 minutes, respectively.

#### 50 mg/kg, followed by an infusion of 15 mg/kg/hr.

ence of catheter-related bladder discomfort above a moderate grade at 0 h postoperatively was tly lower in the magnesium group than in the control group (13 [22%] vs. 46 [77%]; P < 0.001; k = 0.283; 95% CI, 0.171 to 0.467; absolute risk reduction = 0.55; number needed to treat = 2); sults were observed for catheter-related bladder discomfort above a moderate grade at 1 and 2 h tively (5 [8%] *vs.* 17 [28%]; *P* = 0.005; relative risk = 0.294; 95% CI, 0.116 to 0.746; and 1 4 [23%]; *P* < 0.001; relative risk = 0.071; 95% CI, 0.010 to 0.526, respectively). Patient n on a scale from 1 to 7 was significantly higher in the magnesium group than in the control  $\pm 0.8 vs. 3.5 \pm 1.0$ ; P < 0.001; 95% CI, 1.281 to 1.919). Magnesium-related adverse effects were icantly different between groups.

#### 50 mg/kg, followed by an infusion of 15 mg/kg/hr.

int of morphine needed during the operation was statistically comparable, slightly less in the m group. The VAS scores were comparable between the two groups. The magnesium group had tly decreased pain levels on coughing at 0 and 1 hours following the procedure.



## PRACTICE CHANGE

- CRNAs in a level II trauma center in Florida, were educated via a PowerPoint presentation on the evidence of intraoperative magnesium sulfate 2-4 g to reduce postoperative pain and opioid use.
- Education was supplemented with a Q&A session and laminated flyers in the OR's.
- Post education, providers verbalized a strong interest in incorporating magnesium sulfate into their anesthetic plan of care.
- Additional practice change includes relocation of magnesium sulfate bags from remote areas to Omnicell in each OR to facilitate ease of administration.
- Data pending includes number of magnesium sulfate bags used 2 months prior to implementation and 2 months post implementation.



**REFERENCES** 



WEBSITE